Cowen & Co. Believes Argenx Se (NASDAQ: ARGX) Still Has Room to Grow

By Austin Angelo

Cowen & Co. analyst Boris Peaker maintained a Buy rating on Argenx Se (NASDAQ: ARGX) today. The company’s shares closed yesterday at $98.30, close to its 52-week high of $103.

According to TipRanks.com, Peaker is a 5-star analyst with an average return of 16.6% and a 52.8% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Stemline Therapeutics Inc, Mersana Therapeutics Inc, and CytomX Therapeutics Inc.

Currently, the analyst consensus on Argenx Se is Strong Buy and the average price target is $115.67, representing a 17.7% upside.

In a report issued on June 7, Piper Jaffray also reiterated a Buy rating on the stock with a $130 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $103 and a one-year low of $19. Currently, Argenx Se has an average volume of 114.9K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

argenx SE is a clinical-stage biotechnology company, which engages in the research and development of human monoclonal antibodies for the treatment of cancer and oncological, autoimmune, and inflammatory diseases. Its products include ARGX-113 for severe autoimmune diseases and ARGX-110 for T-cell lymphoma and acute myeloid leukemia.